



TGEX-SCBlue-Zeo Expression Vector

INSTRUCTION MANUAL

TGEX-SCBlue-Zeo Mammalian Expression Vector

Catalog #: MX024

Version: A1.2 – February 2024

Table of Contents

| | |
|--|-----------|
| Limited Use License for TGEX Vector Series | 4 |
| Description | 5 |
| Introduction | 5 |
| Content, Shipping & Storage | 5 |
| Limited Product Warranty | 5 |
| TGEX Vector Series | 6 |
| Vector Map | 7 |
| Cloning Site | 7 |
| Feature Table | 8 |
| Restriction Site Summary | 9 |
| Experimental Procedures | 11 |
| General Molecular Biology Techniques | 11 |
| Plasmid Maintenance | 11 |
| Cloning into TGEX-SCblue-Zeo | 11 |
| Sequencing of Inserts | 11 |
| Antibody Expression | 12 |
| Appendix | 13 |
| MSDS Information | 13 |
| Quality Control | 13 |
| Technical Support | 13 |
| References | 13 |

Limited Use License for the TGEX Vector Series

As a condition of sale of this product to you, and prior to using this product, you must agree to the terms and conditions of this license. Antibody Design Labs grants to the buyer with the sale of any of its **TGEX™** vectors (the “Product”) a non-exclusive, non-transferable and limited license to use the Product in research only conducted by the buyer. Such license specifically excludes the right to sell or otherwise transfer the Product, its components or derivatives thereof to third parties. No modifications to the Product may be made without express written permission from Antibody Design Labs. The buyer is not granted a license to use the Product for human or animal therapeutic, diagnostic, or prophylactic purposes.

Antibody Design Labs does not warrant that the use or sale of the Product, the use thereof in combination with other products, or the use of the Product in the operation of any process will not infringe the claims of any United States or other patent(s).

If the buyer is not willing to accept the limitations of this license, without modification, buyer may refuse this license by returning the Product unopened and unused. By keeping or using the Product, buyer implicitly agrees to be bound by the terms of this license.

Entities wishing to use the Product for commercial purposes are required to obtain a license from Antibody Design Labs. Commercial purposes may include, but are not limited to: use of the Product in manufacturing, use of the Product to provide a service, use of the Product for therapeutic or diagnostic purposes, or resale of the Product, whether or not such Product is resold for use in research. For information on purchasing a commercial license to the Product, please contact a licensing representative by phone at (858) 480-6213 or by e-mail at info@abdesignlabs.com.

All trademarks are the property of their respective owners.

Description

Introduction

The **TGEX™** vector series is designed for the rapid expression of antibody molecules by transient gene expression in mammalian cells in suspension culture. This new series, version 7, also allows the selection of stable transformants through the use of Zeocin®. This vector series features a cytomegalovirus (CMV) promoter, the adenovirus tripartite leader sequence (TPL) (Logan 1984, Mariati 2010), a composite leader sequence (hybrid between a mammalian kappa leader and the bacterial pelB leader (Valadon 2006)) followed by a universal double-inverted BsaI cloning site to insert antibody variable regions. The constant regions are derived from species-specific IgG, kappa and lambda sequences. The 3' end on the transcription unit is composed of an IRES element, the Zeocin-resistance gene (Sh ble from *Streptoalloteichus hindustanus*), a Woodchuck hepatitis virus post-transcriptional regulatory element, and the rabbit beta-globin polyadenylation signal. Transfection of the **TGEX™** expression vectors harboring antibody variable region inserts in widely available cell lines using large-scale transfection technologies (see experimental procedure) typically yields antibody titers between 50 and 250 mg/L in serum-free conditions in just a few days.

The **TGEX™-SCblue-Zeo** vector is designed for the transient mammalian expression of scFv-Fc fusions after transfer of scFv fragments from the **PADL™** phagemid vector series. **TGEX™-SCblue-Zeo** vector enables rapid and convenient expression of scFv fragment isolated by phage display as dimeric scFv-Fc fusion with all the advantages conferred by the Fc fragment for detection using commercially available secondary antibodies. The pelBK signal peptide responsible for the secretion of the Fc fusion in the culture supernatant is a composite between a mammalian kappa leader sequence and the bacterial pelB leader sequence with a compatible SfiI restriction site for the transfer (Valadon 2006). Proper recombinant clones can be isolated using a blue/white colony screening.

Content, Shipping & Storage

Content

| VECTOR | COMPOSITION | AMOUNT |
|-----------------|--|--------|
| TGEX-SCBlue-Zeo | 20 µl at 0.5 µg/µl of DNA vector in DNA Conservation Buffer (Tris-HCL 5 mM, EDTA 0.1 mM, pH 8.5) | 10 µg |

Shipping & Storage

TGEX-SCBlue-Zeo vector is shipped on wet ice. Upon receipt, store the vector at -20°C.

Limited Product Warranty

This warranty limits our liability to the replacement of this product. No other warranties of any kind express or implied, including, without limitation, implied warranties of merchantability or fitness for a particular purpose, are provided by Antibody Design Labs. Antibody Design Labs shall have no liability for any direct, indirect, consequential, or incidental damages arising out of the use, the results of use, or the inability to use this product.

For research use only; not intended for any animal or human therapeutic or diagnostic use.

TGEX™ Vector Series

TGEX™ vectors for desired isotypes

| VECTOR | CATALOG | ISOTYPE | DESCRIPTION |
|-------------------------|---------|-------------------|--|
| TGEX™-HC-hG1-Zeo | MX026 | Human IgG1 | Heavy chain expression plasmid for human IgG1 |
| TGEX™-FH-hG1-Zeo | MX023 | Human IgG1 CH1 | For the expression of human IgG1 Fab fragments |
| TGEX™-FC-hG1-Zeo | MX025 | Human IgG1 Fc | For the expression of human IgG1 Fc fusions |
| TGEX™-HC-hG2-Zeo | MX027 | Human IgG2 | Heavy chain expression plasmid for human IgG2 |
| TGEX™-HC-hG3-Zeo | MX028 | Human IgG3 | Heavy chain expression plasmid for human IgG3 |
| TGEX™-HC-hG4[S228P]-Zeo | MX029 | Human IgG4[S228P] | Heavy chain expression plasmid for human IgG4 |
| TGEX™-LC-hK-Zeo | MX030 | Human Kappa | Light chain expression plasmid for human Kappa |
| TGEX™-LC-hL2-Zeo | MX031 | Human Lambda 2 | Light chain expression plasmid for human Lambda 2 |
| TGEX™-HC-mG1-Zeo | MX032 | Murine IgG1 | Heavy chain expression plasmid for murine IgG1 |
| TGEX™-HC-mG2a-Zeo | MX033 | Murine IgG2a | Heavy chain expression plasmid for murine IgG2a |
| TGEX™-HC-mG2b-Zeo | MX034 | Murine IgG2b | Heavy chain expression plasmid for murine IgG2b |
| TGEX™-HC-mG3-Zeo | MX035 | Murine IgG3 | Heavy chain expression plasmid for murine IgG3 |
| TGEX™-LC-mK-Zeo | MX036 | Murine Kappa | Light chain expression plasmid for murine Kappa |
| TGEX™-LC-mL1-Zeo | MX037 | Murine Lambda 1 | Light chain expression plasmid for murine Lambda 1 |
| TGEX™-LC-mL2-Zeo | MX038 | Murine Lambda 2 | Light chain expression plasmid for murine Lambda 2 |
| TGEX™-HC-rbG-Zeo | MX039 | Rabbit IgG | Heavy chain expression plasmid for rabbit IgG |
| TGEX™-LC-rbKb4-Zeo | MX040 | Rabbit Kappa | Light chain expression plasmid for rabbit Kappa |
| TGEX™-HC-dG1-Zeo | MX046 | Dog IgG1 | Heavy chain expression plasmid for dog IgG1 |
| TGEX™-HC-dG2-Zeo | MX047 | Dog IgG2 | Heavy chain expression plasmid for dog IgG2 |
| TGEX™-HC-dG3-Zeo | MX048 | Dog IgG3 | Heavy chain expression plasmid for dog IgG3 |
| TGEX™-HC-dG4-Zeo | MX049 | Dog IgG4 | Heavy chain expression plasmid for dog IgG4 |
| TGEX™-LC-dK-Zeo | MX050 | Dog Kappa | Light chain expression plasmid for dog Kappa |
| TGEX™-LC-dL-Zeo | MX051 | Dog Lambda | Light chain expression plasmid for dog Lambda |

TGEX™ vectors for Fc-engineered antibodies


| VECTOR | CATALOG | ISOTYPE | DESCRIPTION |
|---------------------------|---------|-------------------|--|
| TGEX™-HC-hG1[EA]-Zeo | MX041 | Human IgG1 | Human IgG1 heavy chain with increased ADCC/CDC <i>in vitro</i> |
| TGEX™-HC-hG1[NA]-Zeo | MX042 | Human IgG1 | Human IgG1 aglycosylated heavy chain |
| TGEX™-HC-hG1[LALA-PG]-Zeo | MX043 | Human IgG1 | Human IgG1 heavy chain with decreased ADCC/CDC <i>in vitro</i> |
| TGEX™-HC-hG1[YTE-KF]-Zeo | MX044 | Human IgG1 | Human IgG1 heavy chain with increased serum half-life |
| TGEX™-HC-hG4[SPLE-PG]-Zeo | MX045 | Human IgG4[S228P] | Human IgG4 heavy chain with decreased ADCC/CDC <i>in vitro</i> |

TGEX™ control vector, universal expression and Fc fusions

| VECTOR | CATALOG | USE | DESCRIPTION |
|------------------|---------|---------------------|--|
| TGEX™-AC-Zeo | MX020 | Any expressions | Universal expression vector |
| TGEX™-eGFP-Zeo | MX022 | Transfection | Control plasmid for monitoring transient transfections |
| TGEX™-SCblue-Zeo | MX024 | scFv cloning vector | For the transfer of scFv from any PADL phagemid vector and expression as an scFv-Fc fusion |

Vector Map

The figure below illustrates the main features of **TGEX-SCBlue-Zeo** expression vector. The full vector sequence is available online for download in varied formats on the product web page; the total length of the vector is 5917 bp.



Cloning Site

Following is an illustration of **TGEX-SCBlue-Zeo** cloning site from the EcoRI site and onward. The scFv is inserted in a double inverted BsaI cloning site located between the pelBK leader sequence and the constant regions. The four base pair overhangs after a restriction digestion with BsaI are boxed and grayed.

```

          tgex-S3                                     EcoRI
          ────────────────────────────────────────────┘
971  GAAAGGCGTC TAACCAAGTCA CAGTCGCAAG TTTAAACGGA TCTCTAGCGA
          pelBK leader sequence
          MetGluThrA spThrLeuLe uLeuTrpVal
1021  ATTCGGCTTG GGCCGCCACC ATGGAGACAG ACACACTCCT GCTATGGGTA
          SfiI BglI                                     lacZ
          | |                                         ────┘
          LeuLeuLeuL euAlaAlaGl nProAlaMet Ala
1071  CTGCTGCTCT TAGCGGCCCA GCCGGCCATG GCGCCCAATA CGCAAACCGC
          1121  CTCTCCCCGC GCGTTGGCCG ATTCATTAAT GCAGCTGGCA CGACAGGTTT
          1171  CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAATG TGAGTTAGCT
          1221  CACTCATTAG GCACCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT
          Alpha-B-gal
          ────┘
          MetTh
1271  TGTGTGGAAT TGTGAGCGGA TAACAATTTT ACACAGGAAA CAGCTATGAC
  
```

rMetIleThr AspSerLeuA laValValLe uGlnArgArg AspTrpGluA
 1321 CATGATTACG GATTCACCTGG CCGTCGTTTT ACAACGTCGT GACTGGGAAA

snProGlyVa lThrGlnLeu AsnArgLeuA laAlaHisPr oPropheAla
 1371 ACCCTGGCGT TACCCAACCTT AATCGCCTTG CAGCACATCC CCCTTTCGCC

SerTrpArgA snSerGluGl uAlaArgThr AspArgProS erGlnGlnLe
 1421 AGCTGGCGTA ATAGCGAAGA GGCCCGCACC GATCGCCCTT CCCAACAGTT

Sfil BglI Linker huIgG1-FC

uArgSerLeu Asn... GlyPr oGlyGlyPro GluProLysS
 1471 GCGCAGCCTG AATTAAAATA GATAGGGCCCG GGGAGGCCCGC GAGCCCAAAT

Pro -> Ser mutation
 |

erSerAspLy sThrHisThr CysProProC ysProAlaPr oGluLeu...
 1521 CTTCTGACAA AACTCACACA TGCCACCGT GCCCAGCACC TGAACCTCC

Feature Table

The features of **TGEX-SCBlue-Zeo** transient expression vector are highlighted in the following table.

| FEATURE | LOCATION | DESCRIPTION |
|---------------------|------------|---|
| Promoter | 5-585 | CMV promoter. |
| TPL | 612-1000 | Adenovirus tripartite leader sequence (Logan 1984, Mariati 2010). |
| pelBK leader | 1041-1103 | Hybrid kappa/pelB leader peptide sequence. The cleavage occurs on the C-terminal side of the terminal alanine. |
| lacZ | 1104-1495 | LacZ fragment with lac promoter. |
| Alpha-B-gal | 1316-1486 | B-gal alpha fragment. |
| Human IgG1-FC CDR | 1511-2210 | Sequence encoding the human IgG1 FC sequence comprising the CH2, and CH3 domains with the hinge region. The sequence is intronless; the C-terminal lysine residue is encoded. |
| IRES | 2235-2808 | Internal Ribosome Entry Site. |
| Zeo | 2842- 3216 | Sh ble gene from <i>Streptoalloteichus hindustanus</i> conferring resistance to Zeocin. |
| WPRE | 3225-3813 | Woodchuck hepatitis virus post-transcriptional regulatory element. |
| BGpA | 3829-3927 | Rabbit beta-globin polyadenylation signal sequence. |
| pMB1 origin | 4001 -4620 | pBR322 origin for replication in <i>E. coli</i> with a temperature-sensitive high copy-number phenotype (Lin-Chao 1992). |
| TEM1 beta-lactamase | 5635-4775 | Ampicillin resistance for selection in <i>E. coli</i> . |

Restriction Site Summary

| Enzyme | Site | Nb | Position | Strand | Isoschizomers |
|----------|------------------------------|----|----------|--------|---|
| AlfI | (10/12) GCANNNNNNTGC (12/10) | 1 | 3179 | | |
| ArsI | (8/13) GACNNNNNNNTTYG (11/6) | 1 | 851 | | |
| AvrII | C^CTAGG | 1 | 2386 | | AspA2I BlnI XmaJI |
| BamHI | G^GATCC | 1 | 2824 | | |
| BcgI | (10/12) CGANNNNNNTGC (12/10) | 1 | 5364 | | |
| Bpu10I | CCTNAGC (-5/-2) | 1 | 930 | | |
| BsePI | G^CGCGC | 1 | 2878 | | BssHII PauI PteI |
| CspCI | (11/13) CAANNNNNGTGG (12/10) | 1 | 407 | | |
| EcoNI | CCTNN^NNNAGG | 1 | 1789 | | BstENI XagI |
| EcoRI | G^AATTC | 1 | 1019 | | |
| FalI | (8/13) AAGNNNNNCTT (13/8) | 1 | 784 | | |
| FseI | GGCCG^CC | 1 | 3113 | | RigI |
| GsuI | CTGGAG (16/14) | 1 | 4933 | - | BpmI |
| KpnI | GGTAC^C | 1 | 2676 | | Acc65I Asp718I |
| MauBI | CG^CGCGCG | 1 | 2877 | | |
| NarI | GG^CGCC | 1 | 1100 | | DinI EgeI EheI KasI Mly113I PluTI SfoI SspDI |
| NheI | G^CTAGC | 1 | 2213 | | AsuNHI BmtI BspOI |
| NotI | GC^GGCCGC | 1 | 3217 | | CciNI |
| NsiI | ATGCA^T | 1 | 2147 | | EcoT22I Mph1103I Zsp2I |
| OliI | CACNN^NNGTG | 1 | 1642 | | AleI |
| PciI | A^CATGT | 1 | 2725 | | PscI |
| PmaCI | CAC^GTG | 1 | 2549 | | AcvI BbrPI Eco72I PmlI PspCI |
| PmeI | GTTT^AAAC | 1 | 1000 | | MssI |
| SacI | GAGCT^C | 1 | 583 | | Ecl136II EcoICRI Eco53kI Psp124BI SstI |
| SalI | G^TCGAC | 1 | 2836 | | |
| SapI | GCTCTTC (1/4) | 1 | 2179 | - | BspQI LguI PciSI |
| SgrAI | CR^CCGGYG | 1 | 2955 | | |
| SnaBI | TAC^GTA | 1 | 357 | | BstSNI Eco105I |
| SpeI | A^CTAGT | 1 | 18 | | AhlI BcuI |
| XbaI | T^CTAGA | 1 | 2830 | | |
| XhoI | C^TCGAG | 1 | 966 | | Sfr274I Paer7I SlaI |
| AarI | CACCTGC (4/8) | 2 | 2109 | - | PaqCI |
| | | 2 | 2564 | | |
| AlwNI | CAGNNN^CTG | 2 | 1554 | | CaiI PstNI |
| | | 2 | 4366 | | |
| ApaI | GGGCC^C | 2 | 1495 | | Bsp120I PspOMI |
| | | 2 | 2348 | | |
| BalI | TGG^CCA | 2 | 2843 | | MlsI MluNI Mox20I MscI Msp20I |
| | | 2 | 5845 | | |
| BglII | A^GATCT | 2 | 3944 | | |
| | | 2 | 5768 | | |
| BsgI | GTGCAG (16/14) | 2 | 1790 | - | |
| | | 2 | 2159 | | |
| BsmI | GAATGC (1/-1) | 2 | 2381 | - | Mva1269I PctI |
| | | 2 | 2414 | | |
| Bsp1407I | T^GTACA | 2 | 1908 | | BsrGI BstAUI |
| | | 2 | 5879 | | |
| BssSI | CACGAG (-5/-1) | 2 | 4128 | - | BauI Bst2BI |
| | | 2 | 5512 | | |
| Bsu36I | CC^TNAGG | 2 | 1634 | | Eco81I AxyI Bse21I |
| | | 2 | 1676 | | |
| DraIII | CACNNN^GTG | 2 | 2593 | | AdeI |

| | | | | |
|----------|----------------|---|------|---------------------------|
| DrdI | GACNNNN^NNGTC | 2 | 3190 | |
| | | 2 | 1673 | AasI DseDI |
| | | 2 | 4057 | |
| EagI | C^GGCCG | 2 | 3173 | BseX3I BstZI EclXI Eco52I |
| | | 2 | 3218 | |
| Eam1105I | GACNNN^NNGTC | 2 | 1575 | AhdI BmeRI DriI |
| | | 2 | 4843 | |
| FspI | TGC^GCA | 2 | 1470 | Acc16I NsbI |
| | | 2 | 5068 | |
| HindIII | A^AGCTT | 2 | 2807 | |
| | | 2 | 3950 | |
| NdeI | CA^TATG | 2 | 252 | FauNDI |
| | | 2 | 3906 | |
| PvuI | CGAT^CG | 2 | 1450 | Ple19I |
| | | 2 | 5215 | |
| SexAI | A^CCWGGT | 2 | 1947 | CsiI MabI |
| | | 2 | 3005 | |
| SfiI | GGCCNNNN^NGGCC | 2 | 1085 | |
| | | 2 | 1496 | |

Absent Sites:

AanI, AbsI, AccIII, AfeI, AflIII, AgeI, AjuI, AloI, Aor13HI, Aor51HI, AscI, AsiGI, AsiSI, AsuII, BaeI, BarI, BbvCI, BclI, BfrI, BlpI, BoxI, BplI, Bpull02I, Bpul4I, Bsa29I, BsaBI, BsaI, Bse8I, BseAI, BseCI, BseJI, BshTI, BshVI, BsiWI, BsmBI, Bso31I, Bsp119I, Bsp13I, Bsp1720I, Bsp68I, BspDI, BspEI, BspMAI, BspT104I, BspTI, BspTNI, BssNAI, Bst1107I, BstAFI, BstAPI, BstBI, BstEII, BstPAI, BstPI, BstXI, BstZ17I, Bsu15I, BsuTUI, BtuMI, ClaI, CpoI, CspAI, CspI, Eco147I, Eco31I, Eco32I, Eco47III, Eco91I, EcoO65I, EcoRV, Esp3I, FbaI, FspAI, HpaI, I-CeuI, I-PpoI, I-SceI, KflI, Kpn2I, Ksp22I, KspAI, MfeI, MluI, MreI, MroI, MspCI, MunI, NruI, NspV, PI-PspI, PI-SceI, PacI, PaeI, PalAI, PasI, PceI, Pfl23II, PflFI, PinAI, PshAI, PsiI, PspEI, PspLI, PspXI, PsrI, PstI, PsyI, RgaI, RruI, Rsr2I, RsrII, SbfI, SdaI, SfaAI, SfuI, SgfI, SgrDI, SgsI, SmiI, SphI, SrfI, Sse8387I, SseBI, StuI, SwaI, Tth111I, Vha464I, XcmI.

Experimental Procedures

General Molecular Biology Techniques

Molecular biology should be conducted under the supervision of a qualified instructor trained to standard safety practice in a molecular biology laboratory environment. Standard molecular biology procedures can be found in a general molecular biology handbook such as Sambrook (1989).


Plasmid Maintenance

Propagation and maintenance of TEGX vectors is obtained on any *recA1, endA1 E. coli* strain using LB or 2xYT medium supplemented with ampicillin (100 µg/ml) as a selection marker and incubated at 37°C with agitation. TEGX vectors are derivatives of pBR322 with a high copy number origin of replication and usually gives high yields of plasmid DNA with most standard laboratory strains such as XL1-blue or DH5α. The high copy number phenotype is temperature-sensitive and requires incubation at 37°C (Lin-Chao 1992). Some DNA stabilizing strains are known to produce smaller amounts of plasmid DNA. In case of issues, we recommend using XL10-Gold® from Agilent Technologies, Inc., on which TEGX plasmid DNA can be isolated in large quantities.

Cloning into TEGX-SCBlue-Zeo

Primer Design and pelBK Leader Sequence

A complete hybrid leader sequence is necessary for secretion and proper removal of the leader peptide by host proteases. In the following schema, where [NNN] represents the insert sequence and [Xxx] the translated amino acid sequence, the short hexanucleotide ATGGCN must be appended immediately to the first *SfiI* site to obtain a complete hybrid leader encoding sequence.



Transfer from PADL Phagemid Vectors

scFv fragments and VHH domains can be excised from PADL™ phagemids by *SfiI* or alternatively by *BglII* and cloned directly into TEGX-SCblue opened by *SfiI*. Classical blue/white screen can be applied to detect insert-containing clones; IPTG is dispensable thanks to the very high copy number of TEGX-SCblue.

Sequencing of Inserts

The following primers give a strong PCR amplification of the TEGX vector series inserts between the *EcoRI* site and the *NotI* site. The primer *tgex-S3* can be used to sequence the scFv fragment.

tgex-S3 5'- AGGCGTCTAACCAGTCACAGTC

ires-R 5'- GAATAAGGCCGGTGTGCGTT

Antibody Expression

Cell Lines

Cell lines adapted for culture in suspension and serum-free conditions are recommended. HEK293 and CHO cells are often used for antibody expression by transient transfection; you can either adapt your own cell line or obtain it from a supplier (e.g. Life Technology). HEK293 cells are particularly well suited for expression using **TGEX™** vector series.

Transient Transfection

Many transfection reagents especially designed for transient transfection are commercially available from different providers (e.g. Life Technologies, Mirus Bio LLC). We recommend testing the transfection conditions with a reporter plasmid first to determine the percentage of cells effectively transfected and optimal transfection conditions; fluorescent reporters are often used with that purpose, e.g. TGEX™-eGFP-Zeo (Antibody Design Labs cat# MX022). Similarly, any condition known to boost expression should be carefully tested in your system before being scaled up. We did observe an increase in expression in HEK293 cells upon exposure to sodium valproate (Backliwal 2008). Boosters and enhancers are often included in commercially available transfection kits.

Stable Cell Line Selection

Zeocin can be used very effectively to select stable cell lines secreting antibodies in a few weeks. The following protocol are suggestions that require adjustment to your particular constructs:

WEEK 1.

- Day 0: Transfect in duplicate cells in a 6-well plate containing 2 ml culture per well;
- Day 3-4: Expand each well in two wells with 2 ml culture per well.
- Day 6: Increase the volume to 4 ml per well and add Zeocin at 100 µg/ml.

WEEK 2-3

- Maintain a good cell density and the Zeocin concentration while replenishing the culture with fresh medium as needed.

WEEK 3-4

- Continue selection with possibly a higher Zeocin concentration (up to 1000 µg/ml).
- Proceed to single cloning and analyze stable transformants for expression.

Appendix

MSDS Information

Material Safety Data Sheets are available on Antibody Design Labs website at the corresponding product page.

Quality Control

Specifications and quality control are detailed on the online product page. Antibody Design Labs certifies that the product will perform according to these specifications.

Technical Support

Visit Antibody Design Labs website at www.abdesignlabs.com for technical resources, including manuals, vector maps and sequences, application notes, FAQs, etc.

For more information or technical assistance, call, write, or email us at:

Antibody Design Labs

4901 Morena Blvd, Suite 203

San Diego, CA 92117

Email: support@abdesignlabs.com

Phone: 1-877-223-3104 (Toll Free)

(Monday – Friday 9:00 AM – 5:00 PM PST)

References

1. Logan J, & Shenk T. (1984). Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection. *Proc Natl Acad Sci USA*, 81(12):3655–9.
2. Mariati, Ho SCL, Yap MGS, & Yang Y. (2010). Evaluating post-transcriptional regulatory elements for enhancing transient gene expression levels in CHO K1 and HEK293 cells. *Protein Expr Purif*, 69(1):9–15.
3. Valadon P, Garnett JD, Testa JE, Bauerle M, Oh P, & Schnitzer JE. (2006). Screening phage display libraries for organ-specific vascular immunotargeting in vivo. *Proc Natl Acad Sci USA*, 103(2):407–12.
4. Lin-Chao S, Chen WT, Wong TT (1992). High copy number of the PUC plasmid results from a ROM/ROP-suppressible point mutation in RNA II. *Mol Microbiol*, 6(22):3385–93.
5. Sambrook J, Fritsch EF, & Maniatis T. (1989). In *Molecular cloning: A laboratory manual*. Cold Spring Harbor Laboratory Press, NY, VOL. 1, 2, 3.
6. Backliwal G, Hildinger M, Kuettel I, Delegrange F, Hacker DI, Wurm FM. (2008). Valproic acid: A viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures. *Biotechnol Bioeng*, 101(1):182–9.

This product is subject to Antibody Design Labs Terms & Conditions of Sales available online at <http://www.abdesignlabs.com/terms/>.

© 2024 Antibody Design Labs. All rights reserved.
